



MINISTERIO  
DE ECONOMÍA  
Y COMPETITIVIDAD

*isc*  
Instituto  
de Salud  
Carlos III

# **FP9 - Horizon Europe y misiones**

**Reunión CCAA, Madrid  
23.05.2018**

**Marta Barrionuevo Hafner  
Técnico de Enlace Oficina Bruselas  
Oficina de Proyectos Europeos, SG Internacionales**

# Contexto y Calendario



**2 May 2018: EC  
Communication  
Multiannual Financial  
Framework 2021-2027**

**7 June 2018: Publication of legislative package of  
FP9 – Horizon Europe**

# Programación y Gobernanza FP9

**Sept. 2018**  
**Strategic orientations**

Commissioners

**End 2018**

**Draft strategic R&I plan**

DGs

**Early 2019**

**MS Gathering to discuss strategic plan**

**Summer 2020**

**Adoption first FP9  
WP 2021-22**

**Autumn 2018**  
**Informal soundings MEPs & MS**

**Throughout 2019**  
**Consultation stakeholders and public**

**Early 2020**  
Drafting WPs

*Reunión CCAA, 23 mayo 2018, Madrid*

# Preparación FP9

1. Evaluation of previous FPs
  - Final evaluation FP7
  - Interim - evaluation of H2020
2. Expert studies to prepare FP9
  - Economic rationale for public support for R&I
  - Lamy report: investing in the future we want (LAB-FAB-APP)
  - The Bohemia foresight study

# Estructura Horizon Europe

\* €97,6bn

## Part I: Open Science

European Research Council (ERC)

Marie Skłodowska-Curie Actions (MSCA)

Research Infrastructures

## Part II: Global Challenges and Industrial Competitiveness

1. Health
2. Resilience and Security
3. Digital and Industry
4. Climate, energy and mobility
5. Food and natural resources
6. Non-nuclear direct actions of the JRC

## Part III: Open Innovation

European Innovation Council (EIC)

- Pathfinder for Advanced Research
- Accelerator
- Additional activities of the EIC

## Part IV: Strengthening the European Research and Innovation Area

Spreading Excellence

Reforming and enhancing the EU Research and Innovation System

Knowledge and tools for policy-making

# Misiones - Características

## Mission-oriented result

Expert opinions on mission-oriented R&I

- Economic & Societal Impact of Research (ESIR)
- Research, Innovation and Science high-level group (RISE)
- The Mazzucato report

- Missions are bold, inspirational with **wide societal relevance**
- Have a clear direction: **targeted, measurable** and **time-bound**
- Ambitious but **realistic** in terms of R&I
- Contain activities **cutting across** scientific **disciplines, policy sectors** and include **many types of actors**
- Allow for multiple **bottom-up solutions**
- Have **EU-added value**

# **Ejemplo** -*Fighting Dementia: healthy brains for better life*

1. Mission Statement
2. Underlying challenge/opportunity
3. Activities
4. Topic
5. KPIs and specific targets
6. Mission Board & Executive Agency

# 1. Mission Statement

## Dementia

Reduce by half the human burden of dementia and add more healthy years by avoiding or delaying occurrence and reducing progression of the disease within 10 years. This requires better prevention, early detection and early intervention, in order to give more healthy life years to millions of people, lower the burden for caregivers and contain costs for society.



# 2. Underlying challenge/opportunity

## Dementia

Dementia refers to a set of diseases that includes Alzheimer, stroke etc. It affects 10.5 million people in Europe, at a cost of some €270 billion a year, and is expected to rise by 78% and affect 18.7 million people by 2050.<sup>3</sup> This is a huge global challenge and an opportunity for Europe to enhance patient-centred approaches through the development of new technologies, drugs and services for monitoring, early diagnosis, treatment and care. This would also allow enhancing new markets for drugs and services, including through social innovation.

Awareness of dementia disease is low, prevention is limited and underdiagnosed or diagnosed late. Concomitant diseases are also under-reported, which in turn can accelerate decline in health and quality of life for patients and their families. In addition, there is no effective treatment and care can also be improved.

Large investments in transdisciplinary research are needed, but equally better coordination and collaboration among the major efforts deployed in both the public and private sectors, including national programmes, research infrastructures and partnerships.

# 3. Activities

## Dementia

- 1) Understanding the origins of dementia and identifying risk factors to enable better prevention, diagnosis and treatment.
- 2) Effecting behavioural changes at population level to avoid or delay the onset of dementia.
- 3) Accelerate research through European or global initiative(s) bringing together resources and expertise.
- 4) Improving drug-development to provide therapies for Alzheimer's and other causes of dementia.
- 5) Determining the main factors that affect disability and quality of life, better monitor the effectiveness of drugs and other interventions

6) Develop digital approaches to provide patients and carers with the means to prevent and alleviate memory loss (through physical & mental activity and social interaction), improve compliance, monitor symptoms or provide support to enhance independence and support assisted living.

### **Outside Framework programme for R&I**

7) Establishing a clinical trial network covering all MS to accelerate the validation of new therapies and ensure rapid, broad and equitable access. [Structural funds – cohesion policy]

8) Assessing strengths/weaknesses of formal and informal care approaches and infrastructures across Europe, including the principles of access and equity, as a prelude to implementing best practices and evidence-based systems.  
[DG SANTE]

# 4. Topics Dementia

1. A **topic** to cover the research and innovation activities, including leveraging infrastructures – **bottom-up**
2. A **partnership programme** to cover: **supply and demand side**
  - a. Comprehensive coordination of national strategies and research programmes;
  - b. Partnerships with charities and philanthropic organisations;
  - c. Large-scale academia-industry and intra-industry collaboration, including small and medium-sized technology driven enterprises;
  - d. Develop an ecosystem enabling rapid growth of emerging enterprises;
  - e. International collaboration increased through programme level cooperation;
3. A topic for **incentives/prizes** for specific cases (e.g. pre-symptomatic diagnostics, assisted living, social innovation); **not bottom up but target particular needs**
4. A topic for **Innovative procurement** for health uptake.

Differences from normal calls: cross-cutting

# Implementación misiones

## Mission Boards

- Members appointed on personal bases + experts + EC services
- Call for interest
- Propose missions to EC + advice on implementation
- Co-design process
- Identification evaluators
- Impact indicators
- Monitoring and communicating progress
- Reaching out to stakeholders

## Executive Agency and Mission manager (3-5 years)

- Recruit top experts + mission manager in the field
- Manage portfolio of FP9 supported activities
- Monitoring of missions (baseline study)

# 5. KPIs and specific targets

## Dementia

- Average diagnosis 3 years earlier;
- Onset of dementia delayed by 5 years;
- Reduce by 50% the progression of dementia in affected patients;
- Impact on costs (TBD);
- Develop an appropriate evaluation system adapted to various development stages of dementia;
- XX % of patients monitored at home (with XX% less visits to doctor/hospital);
- Develop M-ApPs for the monitoring, predictions and support which are clinically validated;
- Measures of physical & mental activity and social interaction;
- 10% of AD patients benefiting from the most innovative therapies (e.g. under clinical trials);
- 10 indicators validated for very early detection of disease;
- 5 new interventions (drug or non-drug) clinically validated with significant patients' benefit.


Mission Board  
and mission  
manager

# 6. Mission Board

## Dementia

- Celebrity: XXX YYY (should be an active middle-aged person)
- 5-7 end-users: patients, formal and informal caregivers, payers (eg Alzheimer Europe, Stroke Alliance for Europe (SAFE), European Patient Forum (EPF), European Federation of Nurses Associations (EFN), *European Brain Council (EBC)*...)
- 3-4 DGs: SANTE / CNECT / JRC / MOVE\* / EMPL (\*smart cities / linked to physical activity)
- 2-3 representatives from MS

# Fases de diseño misiones





¡Gracias!

[mbarrionuevo@eu-isciii.es](mailto:mbarrionuevo@eu-isciii.es)

*Reunión CCAA, 23 mayo 2018, Madrid*